IOP Clinical Trials

743 recruitingLast updated: June 18, 2026

There are 743 actively recruiting iop clinical trials across 71 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Paris, France, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


IOP Trials at a Glance

743 actively recruiting trials for iop are listed on ClinicalTrialsFinder across 6 cities in 71 countries. The largest study group is Not Applicable with 244 trials, with the heaviest enrollment activity in New York, Paris, and Beijing. Lead sponsors running iop studies include Assistance Publique - Hôpitaux de Paris, University Hospital, Montpellier, and Cairo University.

Treatments under study

About IOP Clinical Trials

Looking for clinical trials for IOP? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new IOP trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about IOP clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 743 trials

Recruiting
Phase 3

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Turner SyndromeIdiopathic Short StatureShort Stature Homeobox Gene Mutation+1 more
Ascendis Pharma A/S186 enrolled19 locationsNCT07221851
Recruiting
Not Applicable

Simulation Trial of Telemedical Support for Paramedics

Acute Respiratory FailureEmergenciesCardiopulmonary Arrest+1 more
Boston Medical Center420 enrolled9 locationsNCT06441760
Recruiting

Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement

Sentinel Lymph Node Biopsy (SLNB)ALNDTargeted Axillary Dissection (TAD)
European Institute of Oncology150 enrolled14 locationsNCT07278726
Recruiting
Phase 2

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Idiopathic CD4-PositiveT-Lymphocytopenia
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT02015013
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 2Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic PurpuraITPIdiopathic Thrombocytopenic Purpura+4 more
argenx24 enrolled10 locationsNCT07194850
Recruiting

POCD After Major Gynecologic Surgery

Postoperative Cognitive DysfunctionPerioperative Neurocognitive Disorder
Fatihhan Zeytun72 enrolled1 locationNCT07589348
Recruiting
Phase 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Mediar Therapeutics164 enrolled69 locationsNCT06967805
Recruiting
Phase 3

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

Polyarticular Course Juvenile Idiopathic Arthritis
Alfasigma S.p.A.65 enrolled14 locationsNCT07554495
Recruiting
Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled373 locationsNCT06238622
Recruiting
Phase 2

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals200 enrolled57 locationsNCT06393712
Recruiting
Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Contineum Therapeutics324 enrolled22 locationsNCT07284459
Recruiting

UNderstanding the Causes Of Idiopathic Scoliosis Through the Longitudinal Analysis of Proteomic Markers: the UNCOIL Study

Adolescent Idiopathic Scoliosis (AIS)Neuromuscular Scoliosis
University of Colorado, Denver500 enrolled1 locationNCT07634627
Recruiting
Early Phase 1

First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer

Metastatic Breast CancerCancerMetastatic Prostate Cancer+5 more
Integrated Haematology and Oncology Network20 enrolled1 locationNCT07608848
Recruiting

BEAT-SHOCK Registry

Cardiogenic ShockMyocardial Infarction (MI)Acute Decompensated Heart Failure+4 more
University Hospital, Basel, Switzerland8,000 enrolled1 locationNCT07643610
Recruiting

Lung and Heart Function Across Decades of Life in Health

DyspneaPollution; ExposurePollution Related Respiratory Disorder+1 more
University of California, San Francisco200 enrolled1 locationNCT07641413
Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory MyopathyAnti-synthetase Syndrome+5 more
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting
Phase 2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim71 enrolled46 locationsNCT07036523
Recruiting
Not Applicable

Preoperative Hemodialysis Timing in Patients With End-Stage Kidney Disease: The POD-ESKD Pilot Trial

End Stage Kidney Disease (ESRD)HemodialysisPerioperative Management
Stanford University30 enrolled1 locationNCT07339202
Recruiting
Phase 2

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Parkinson DiseaseParkinsonParkinson Disease, Idiopathic+2 more
Neuron23 Inc.150 enrolled70 locationsNCT06680830